{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:10:47Z","timestamp":1791295847296,"version":"4.1.0"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":101,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2015,8]]},"abstract":"<jats:p>3\u2010hydroxy\u20103\u2010methylglutaryl coenzyme A reductase inhibitors (statins) have been variably noted to affect hepatitis C virus (HCV) treatment response, fibrosis progression, and hepatocellular carcinoma (HCC) incidence, with some having a more potent effect than others. We sought to determine the impact of adding statins to antiviral therapy upon sustained virological response (SVR) rates, fibrosis progression, and HCC development among HCV\u2010infected persons using the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES), an established, longitudinal, national cohort of HCV\u2010infected veterans. Within ERCHIVES, we identified those who received HCV treatment and a follow\u2010up of &gt;24 months after treatment completion. We excluded those with human immunodeficiency virus coinfection, hepatitis B surface antigen positivity, cirrhosis, and HCC at baseline. Our main outcomes were liver fibrosis progression measured by FIB\u20104 scores, SVR rates, and incident HCC (iHCC). Among 7,248 eligible subjects, 46% received statin therapy. Statin use was significantly associated with attaining SVR (39.2% vs. 33.3%; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009&lt;\u20090.01), decreased cirrhosis development (17.3% vs. 25.2%; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009&lt;\u20090.001), and decreased iHCC (1.2% vs. 2.6%; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009&lt;\u20090.01). Statins remained significantly associated with increased odds of SVR (odds ratio\u2009=\u20091.44; 95% confidence interval [CI]\u2009=\u20091.29, 1.61), but lower fibrosis progression rate, lower risk of progression to cirrhosis (hazard ratio [HR]\u2009=\u20090.56; 95% CI\u2009=\u2009\u22120.50, 0.63), and of incident HCC (HR\u2009=\u20090.51; 95% CI\u2009=\u20090.34, 0.76) after adjusting for other relevant clinical factors. <jats:italic toggle=\"yes\">Conclusions<\/jats:italic>: Statin use was associated with improved virological response (VR) rates to antiviral therapy and decreased progression of liver fibrosis and incidence of HCC among a large cohort of HCV\u2010positive Veterans. These data support the use of statins in patients with HCV. (Hepatology 2015) H<jats:sc>epatology<\/jats:sc> 2015;62:365\u2013374<\/jats:p>","DOI":"10.1002\/hep.27835","type":"journal-article","created":{"date-parts":[[2015,4,6]],"date-time":"2015-04-06T22:11:25Z","timestamp":1428358285000},"page":"365-374","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":101,"title":["Effect of addition of statins to antiviral therapy in hepatitis C virus\u2013infected persons: Results from ERCHIVES"],"prefix":"10.1097","volume":"62","author":[{"given":"Adeel A.","family":"Butt","sequence":"first","affiliation":[{"name":"VA Pittsburgh Healthcare System,Pittsburgh,PA"},{"name":"University of Pittsburgh School of Medicine,Pittsburgh,PA"},{"name":"Hamad Healthcare Quality Institute, Hamad Medical Corporation,Doha,Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yan","sequence":"additional","affiliation":[{"name":"VA Pittsburgh Healthcare System,Pittsburgh,PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Bonilla","sequence":"additional","affiliation":[{"name":"ImmunoScience Inc.,Pleasanton,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul\u2010Badi","family":"Abou\u2010Samra","sequence":"additional","affiliation":[{"name":"Hamad Healthcare Quality Institute, Hamad Medical Corporation,Doha,Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obaid S.","family":"Shaikh","sequence":"additional","affiliation":[{"name":"VA Pittsburgh Healthcare System,Pittsburgh,PA"},{"name":"University of Pittsburgh School of Medicine,Pittsburgh,PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey G.","family":"Simon","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital,Boston,MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond T.","family":"Chung","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital,Boston,MA"},{"name":"Harvard Medical School,Boston,MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari S.","family":"Rogal","sequence":"additional","affiliation":[{"name":"VA Pittsburgh Healthcare System,Pittsburgh,PA"},{"name":"University of Pittsburgh School of Medicine,Pittsburgh,PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) Study Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2015,5,23]]},"reference":[{"key":"hep27835-bib-0001-20241017","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tem.2009.07.005","article-title":"Hepatitis C virus hijacks host lipid metabolism","volume":"21","year":"2010","journal-title":"Trends Endocrinol Metab"},{"key":"hep27835-bib-0002-20241017","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000354541","article-title":"Impact of added fluvastatin to standard\u2010of\u2010care treatment on sustained virological response in naive chronic hepatitis C Patients infected with genotypes 1 and 3","volume":"57","year":"2014","journal-title":"Intervirology"},{"key":"hep27835-bib-0003-20241017","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/jvh.12085","article-title":"A randomized controlled trial adding fluvastatin to peginterferon and ribavirin for naive genotype 1 hepatitis C patients","volume":"20","year":"2013","journal-title":"J Viral Hepat"},{"key":"hep27835-bib-0004-20241017","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2893.2010.01310.x","article-title":"Open\u2010label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C","volume":"18","year":"2011","journal-title":"J Viral Hepat"},{"key":"hep27835-bib-0005-20241017","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.3748\/wjg.15.5020","article-title":"Do statins reduce hepatitis C RNA titers during routine clinical use?","volume":"15","year":"2009","journal-title":"World J Gastroenterol"},{"key":"hep27835-bib-0006-20241017","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jhep.2014.08.013","article-title":"Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C","volume":"62","year":"2015","journal-title":"J Hepatol"},{"key":"hep27835-bib-0007-20241017","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1200\/JCO.2012.44.6831","article-title":"Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection","volume":"31","year":"2013","journal-title":"J Clin Oncol"},{"key":"hep27835-bib-0008-20241017","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/hr.2010.243","article-title":"Protective effects of statin on cardiac fibrosis and apoptosis in adrenomedullin\u2010knockout mice treated with angiotensin II and high salt loading","volume":"34","year":"2011","journal-title":"Hypertens Res"},{"key":"hep27835-bib-0009-20241017","doi-asserted-by":"crossref","first-page":"e14145","DOI":"10.1371\/journal.pone.0014145","article-title":"Statins inhibit angiotensin II\/Smad pathway and related vascular fibrosis, by a TGF\u2010beta\u2010independent process","volume":"5","year":"2010","journal-title":"PLoS One"},{"key":"hep27835-bib-0010-20241017","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1164\/rccm.201108-1574OC","article-title":"Statins and pulmonary fibrosis: the potential role of NLRP3 inflammasome activation","volume":"185","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"hep27835-bib-0011-20241017","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0012-3692(15)31155-7","article-title":"Impact of angiotensin\u2010converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis","volume":"126","year":"2004","journal-title":"Chest"},{"key":"hep27835-bib-0012-20241017","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/hep.21232","article-title":"Different anti\u2010HCV profiles of statins and their potential for combination therapy with interferon","volume":"44","year":"2006","journal-title":"Hepatology"},{"key":"hep27835-bib-0013-20241017","doi-asserted-by":"crossref","first-page":"e96533","DOI":"10.1371\/journal.pone.0096533","article-title":"Matrix conditions and KLF2\u2010dependent induction of heme oxygenase\u20101 modulate inhibition of HCV replication by fluvastatin","volume":"9","year":"2014","journal-title":"PLoS One"},{"key":"hep27835-bib-0014-20241017","doi-asserted-by":"crossref","first-page":"e80304","DOI":"10.1371\/journal.pone.0080304","article-title":"Fluvastatin interferes with hepatitis C virus replication via microtubule bundling and a doublecortin\u2010like kinase\u2010mediated mechanism","volume":"8","year":"2013","journal-title":"PLoS One"},{"key":"hep27835-bib-0015-20241017","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/j.1572-0241.2008.01876.x","article-title":"Fluvastatin inhibits hepatitis C replication in humans","volume":"103","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"hep27835-bib-0016-20241017","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1086\/599371","article-title":"Hepatitis C virus infection and the risk of coronary disease","volume":"49","year":"2009","journal-title":"Clin Infect Dis"},{"key":"hep27835-bib-0017-20241017","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/hep.23000","article-title":"Effect of HCV and its treatment upon survival","volume":"50","year":"2009","journal-title":"Hepatology"},{"key":"hep27835-bib-0018-20241017","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1001\/jamainternmed.2014.6502","article-title":"Liver fibrosis progression in hepatitis C virus infection after seroconversion","volume":"175","year":"2015","journal-title":"JAMA Intern Med"},{"key":"hep27835-bib-0019-20241017","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1089\/aid.2011.0004","article-title":"A comparison of treatment eligibility for HCV in HCV monoinfected vs. HCV\/HIV coinfected persons in ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans)","volume":"27","year":"2011","journal-title":"AIDS Res Hum Retroviruses"},{"key":"hep27835-bib-0020-20241017","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1111\/j.1572-0241.2006.00754.x","article-title":"Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office","volume":"101","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"hep27835-bib-0021-20241017","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1310\/hct1001-25","article-title":"Rates of HCV treatment eligibility among HCV\u2010monoinfected and HCV\/HIV\u2010coinfected patients in tertiary care referral centers","volume":"10","year":"2009","journal-title":"HIV Clin Trials"},{"key":"hep27835-bib-0022-20241017","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1210\/jc.2012-1267","article-title":"Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta\u2010analysis","volume":"97","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"hep27835-bib-0023-20241017","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1002\/cncr.24982","article-title":"Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma","volume":"116","year":"2010","journal-title":"Cancer"},{"key":"hep27835-bib-0024-20241017","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1073\/pnas.0409834102","article-title":"Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids","volume":"102","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"hep27835-bib-0025-20241017","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1086\/597039","article-title":"Antimicrobial and immunomodulatory attributes of statins: relevance in solid\u2010organ transplant recipients","volume":"48","year":"2009","journal-title":"Clin Infect Dis"},{"key":"hep27835-bib-0026-20241017","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1053\/j.gastro.2003.12.007","article-title":"Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis","volume":"126","year":"2004","journal-title":"Gastroenterology"},{"key":"hep27835-bib-0027-20241017","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jhep.2012.08.026","article-title":"The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial\u2010stellate cell deactivation induced by statins","volume":"58","year":"2013","journal-title":"J Hepatol"},{"key":"hep27835-bib-0028-20241017","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/hep.21848","article-title":"Efficacy and safety of high\u2010dose pravastatin in hypercholesterolemic patients with well\u2010compensated chronic liver disease: results of a prospective, randomized, double\u2010blind, placebo\u2010controlled, multicenter trial","volume":"46","year":"2007","journal-title":"Hepatology"},{"key":"hep27835-bib-0029-20241017","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/jgh.12657","article-title":"Severe hepatic injury associated with different statins in patients with chronic liver disease: a nationwide population\u2010based cohort study","volume":"30","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"hep27835-bib-0030-20241017","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1007\/s10620-014-3179-2","article-title":"Statin use in patients with cirrhosis: a retrospective cohort study","volume":"59","year":"2014","journal-title":"Dig Dis Sci"},{"key":"hep27835-bib-0031-20241017","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2012.10.005","article-title":"Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta\u2010analysis","volume":"144","year":"2013","journal-title":"Gastroenterology"},{"key":"hep27835-bib-0032-20241017","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10654-013-9806-y","article-title":"Statin use and risk of hepatocellular carcinoma","volume":"28","year":"2013","journal-title":"Eur J Epidemiol"},{"key":"hep27835-bib-0033-20241017","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.canep.2014.06.009","article-title":"Statin use and risk of hepatocellular carcinoma in a U.S","volume":"38","year":"2014","journal-title":"population. Cancer Epidemiol"},{"key":"hep27835-bib-0034-20241017","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.bbrc.2011.12.091","article-title":"Statins inhibit expression of thioredoxin reductase 1 in rat and human liver and reduce tumour development","volume":"417","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"hep27835-bib-0035-20241017","first-page":"1167","article-title":"Fluvastatin, a lipophilic statin, induces apoptosis in human hepatocellular carcinoma cells through mitochondria\u2010operated pathway","volume":"48","year":"2010","journal-title":"Indian J Exp Biol"},{"key":"hep27835-bib-0036-20241017","first-page":"735","article-title":"Simvastatin inhibits cell growth and induces apoptosis and G0\/G1 cell cycle arrest in hepatic cancer cells","volume":"26","year":"2010","journal-title":"Int J Mol Med"},{"key":"hep27835-bib-0037-20241017","first-page":"879","article-title":"Simvastatin modulates the adhesion and growth of hepatocellular carcinoma cells via decrease of integrin expression and ROCK","volume":"38","year":"2011","journal-title":"Int J Oncol"},{"key":"hep27835-bib-0038-20241017","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000156702","article-title":"Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma","volume":"78","year":"2008","journal-title":"Digestion"},{"key":"hep27835-bib-0039-20241017","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1054\/bjoc.2000.1716","article-title":"Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial","volume":"84","year":"2001","journal-title":"Br J Cancer"},{"key":"hep27835-bib-0040-20241017","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/MAJ.0b013e3181e15da8","article-title":"Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians","volume":"340","year":"2010","journal-title":"Am J Med Sci"},{"key":"hep27835-bib-0041-20241017","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s10620-009-0959-1","article-title":"Statin therapy and serum transaminases among a cohort of HCV\u2010infected veterans","volume":"55","year":"2010","journal-title":"Dig Dis Sci"},{"key":"hep27835-bib-0042-20241017","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1592\/phco.28.4.522","article-title":"Safety of statin therapy in patients with preexisting liver disease","volume":"28","year":"2008","journal-title":"Pharmacotherapy"},{"key":"hep27835-bib-0043-20241017","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4065\/mcp.2009.0365","article-title":"Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma","volume":"85","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"hep27835-bib-0044-20241017","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11739-008-0127-1","article-title":"Dysmetabolic changes associated with HCV: a distinct syndrome?","volume":"3","year":"2008","journal-title":"Intern Emerg Med"},{"key":"hep27835-bib-0045-20241017","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1053-2498(03)00148-7","article-title":"Donor hepatitis\u2010C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation","volume":"23","year":"2004","journal-title":"J Heart Lung Transplant"},{"key":"hep27835-bib-0046-20241017","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/MAJ.0000000000000291","article-title":"Statins and hepatitis C virus infection: an old therapy with new scope","volume":"348","year":"2014","journal-title":"Am J Med Sci"},{"key":"hep27835-bib-0047-20241017","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB\u20104: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest","volume":"46","year":"2007","journal-title":"Hepatology"},{"key":"hep27835-bib-0048-20241017","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1053\/j.gastro.2012.02.017","article-title":"Noninvasive methods to assess liver disease in patients with hepatitis B or C","volume":"142","year":"2012","journal-title":"Gastroenterology"},{"key":"hep27835-bib-0049-20241017","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-158-11-201306040-00005","article-title":"Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review","volume":"158","year":"2013","journal-title":"Ann Intern Med"},{"key":"hep27835-bib-0050-20241017","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/pds.3367","article-title":"Validation of a coding algorithm to identify patients with hepatocellular carcinoma in an administrative database","volume":"22","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.27835","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201508000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:56:38Z","timestamp":1729212998000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201508000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,23]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.27835","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,23]]},"assertion":[{"value":"2015-01-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-04-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}